Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Recruiting

Phase 1

SAR445877 & FOLFOX6, BevacizumabPhase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07500298

Conditions

Phase 1

SAR445877

FOlfox6

Bevacizimab

First Line Treatment

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SAR445877

FOLFOX6

Bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-13. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-01.